3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
5
Phase 2
4
Phase 1/2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Dermatologic
1
Conditions
Colorectal Neoplasms
34
Pancreatic Neoplasms
19
Colonic Neoplasms
10
Rectal Neoplasms
8
Stomach Neoplasms
7
Precursor Cell Lymphoblastic Leukemia-Lymphoma
7
Neoplasms
6
Neoplasm Metastasis
6
Gastrointestinal Neoplasms
6
Esophageal Neoplasms
6
Carcinoma, Non-Small-Cell Lung
5
Biliary Tract Neoplasms
5
Advanced Solid Tumors
4
Triple Negative Breast Neoplasms
3
Melanoma
3
Endometrial Neoplasms
3
Carcinoma, Squamous Cell
3
Adenocarcinoma Of Esophagus
3
Squamous Cell Carcinoma of Head and Neck
2
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Ovarian Neoplasms
2
Liver Neoplasms
2
Esophageal Squamous Cell Carcinoma
2
Carcinoma, Transitional Cell
2
Carcinoma, Hepatocellular
2
Carcinoma
2
Subjects With Resectable Local or Locally Advanced, Non-Metastatic (T2-T4, N0-N3, M0; Stages II and III) and Histologically-Confirmed Intestinal GC
1
Solid Cancer
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Interventions
Gemcitabine
15
pembrolizumab
13
Doxorubicin
13
Radiotherapy
12
Docetaxel
9
Nivolumab
8
Filgrastim
7
Cyclophosphamide
7
pazopanib
6
Ifosfamide
6
130-nm albumin-bound paclitaxel
5
Temozolomide
4
Irinotecan
4
Ipilimumab
4
Imatinib Mesylate
4
Albumin-Bound Paclitaxel
4
talimogene laherparepvec
3
surufatinib
3
pegfilgrastim
3
eribulin
3
atezolizumab
3
Vinorelbine
3
Sirolimus
3
Peripheral Blood Stem Cell Transplantation
3
PM 01183
3
Drug Therapy
3
Cisplatin
3
toripalimab
2
spartalizumab
2
selinexor
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Sarcoma
×
Leucovorin
×
Clear all
NCT03009058
2024-11-25
MODULATE
Immodulon Therapeutics Ltd
Phase 1/2
Terminated
2 enrolled
7 charts